Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase 3 open-label, randomized study of the ALK inhibitors X-396 and crizotinib given as single agents
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.